Immuron Limited
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Steven Lydeamore
- Full Time Employees
- 7
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 62 Lygon Street Blackburn VIC Australia 3053
- IPO Date
- Apr 30, 1999
- Website
- immuron.com.au
- Similar Companies
- Business
- Immuron Limited (ASX:IMC; NASDAQ:IMRN) is an Australia-based biopharmaceutical company focused on the research, development, and commercialization of orally delivered targeted polyclonal antibodies derived from hyper-immune bovine colostrum for the prevention and treatment of enteric diseases and gastrointestinal disorders. The company offers commercial products including Travelan®, an over-the-counter medicine listed on the Australian Register of Therapeutic Goods (AUST L 106709) to reduce the risk of travellers' diarrhoea, minor gastrointestinal disorders, and antimicrobial exposure; Protectyn® (AUST L 231001), an immune supplement supporting healthy digestive function and liver health sold through practitioners in Australia; and ProIBS®, a clinically proven medicine for the relief of irritable bowel syndrome symptoms such as abdominal pain, bloating, and bowel irregularities. Its pipeline includes drug candidates such as Travelan (IMM-124E) in Phase II clinical trials for travellers' diarrhoea prevention with topline results expected in October 2025, IMM-529 in Phase II for recurrent Clostridioides difficile infections with an FDA Investigational New Drug application planned for August 2025, and IMM-986 in preclinical development for Vancomycin-resistant enterococci. Immuron operates in the biopharmaceutical industry with segments in research and development as well as hyper-immune products, targeting consumer health, military, and clinical markets in Australia, the United States, Canada, New Zealand, and through global partnerships. Founded in 1994 and formerly known as Anadis Limited until a name change in December 2008, the company is headquartered at 62 Lygon Street, Carlton South, Victoria, Australia. Recent developments include an exclusive distribution agreement with Calmino Group AB in March 2025 for ProIBS® launch in Australia and New Zealand pharmacies in Q1 2026; a new funded research agreement in August 2024 with the U.S. Naval Medical Research Command and Walter Reed Army Institute of Research to develop enhanced bovine colostrum formulations targeting Campylobacter, enterotoxigenic Escherichia coli, and Shigella pathogens; completion of recruitment for the Travelan Phase II study; strong sales growth projecting over A$7 million for FY2025 versus A$4.9 million in FY2024; and a partnership with InvestorHub announced in August 2025 to enhance investor communications.
Company News
Travelan® Phase 2 Study Results Published
Immuron (NASDAQ:IMRN) Sees Significant Increase in Short Interest
Immuron (NASDAQ:IMRN) Shares Down 2.5% – What’s Next?
Immuron Stock Surges Friday: What's Driving the Action?
Immuron to launch PROIBS® in the United States
Immuron (NASDAQ:IMRN) and Applied Therapeutics (NASDAQ:APLT) Financial Analysis
Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live stream
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00
Immuron Double Digit 3Q Sales Growth
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target
Immuron Reports Continued Sales Growth
Immuron IMM-529 IND approved by FDA
Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target
Immuron Q1 FY26 YoY growth
Immuron Submits IMM-529 IND to FDA
Immuron Letter to Shareholders – Projects Update
Immuron partners with InvestorHub